Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Nurtec ODT / Vydura (rimegepant by Year
Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International revenues ($M) ($M)
Pfizer Nurtec ODT / Vydura (rimegepant: $102M in FY2025, up 47.8% from a year earlier.
Where the FY2025 figure comes from
“|| Nurtec ODT/Vydura | 1,424 | 1,263 | 13% | 13% | 1,322 | 1,193 | 11% | 102 | 69 | 46% | 44%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 102 | +47.8% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 69 | +245.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 20 | +17.6% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 17 | +750.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 2 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
Cite this data
StockData. (2026). Pfizer Nurtec ODT / Vydura (rimegepant ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/nurtec-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.